Nasdaq
$125.43▼ 0.13%vs prev close
🔒 Quotes & buy pressure are MAX onlySee plans
Market cap $14.88BShares out 1.200M sh
Chart
Filings & news by date
Hover (PC) or tap (mobile) a candle to see that day only
Filings
22- 10.8After-hours26.10.09 08:564Ownership#●●●
HALOZYME THERAPEUTICS, INC.
Helen Torley, an executive at Halozyme Therapeutics, reported a change in beneficial ownership of securities on October 6, 2026. This filing is a standard Form 4 disclosure regarding insider stock holdings.…more
$125.43-0.13%vs prev closeDetected5m · 30m · 60m · Next dayPLUSView filingShare
- 10.8After-hours26.10.09 08:554/AOwnership
HALOZYME THERAPEUTICS, INC.
Bernadette Connaughton, an insider at Halozyme Therapeutics, Inc., filed an amended Form 4/A regarding changes in beneficial ownership of securities dated May 5, 2026. This filing serves to correct previously reported information concerning the insider's equity holdings.…more
$125.43-0.13%vs prev closeView filingShare - 10.2After-hours26.10.03 05:434Ownership
HALOZYME THERAPEUTICS, INC.
James M. Daly, an executive at Halozyme Therapeutics, filed a report regarding changes in his beneficial ownership of company securities effective October 1, 2026. This filing serves as an official disclosure of insider equity transactions to the SEC.…more
$125.43-0.13%vs prev closeView filingShare
21 more filings
Sign up free to unlock the full feed and real-time filing & news alerts.
- ✓Free — no card required
- ✓Full real-time filing & news feed
- ✓Daily Today Report
News
GlobeNewswire- 10.7Pre-market26.10.07 21:38Bullish#●●●#●●●
Halozyme Wins Dutch Patent Case, Blocks Merck's Keytruda SC Sales
Halozyme announced that a Dutch court upheld its patent, effectively barring Merck from manufacturing and selling Keytruda SC in several European markets. This legal victory reinforces Halozyme's intellectual property position regarding its proprietary technology.…more
$125.43-0.13%vs prev closeDetected5m · 30m · 60m · Next dayPLUSShareBenzinga
- 10.6After-hours26.10.07 05:06
●●●●●●●● ●●●●● ●●●●●●
Halozyme Therapeutics has expanded its collaboration with argenx to include two additional exclusive targets for its ENHANZE technology. While this broadens the scope of their partnership, specific financial terms of the expanded agreement were not disclosed.…more
$125.43-0.13%vs prev closeShareBenzinga - 9.18Overnight26.09.18 16:08
●●●●●●●● ●●●●● ●●●●●●
Halozyme Therapeutics has priced an upsized offering of $1.3 billion in 1.50% convertible senior notes due 2033. This significant capital raise may lead to concerns regarding potential shareholder dilution.…more
$125.43-0.13%vs prev closeShareBenzinga
2 more news items
Sign up free to unlock the full feed and real-time filing & news alerts.
- ✓Free — no card required
- ✓Full real-time filing & news feed
- ✓Daily Today Report